2022 World Conference on Lung Cancer (ePosters)-EP16.01-021. Less Immune Cell Infiltration and Worse Prognosis for NSCLC Patients with XPO1 Copy Number Alterations

EP16.01-021. Less Immune Cell Infiltration and Worse Prognosis for NSCLC Patients with XPO1 Copy Number Alterations

Pdf Summary

A study conducted by Xuanzong Li et al. at the Shandong Cancer Hospital and Institute in China found that alterations in the XPO1 gene were associated with less immune cell infiltration and worse prognosis in patients with non-small-cell lung cancer (NSCLC). The researchers examined the prevalence of XPO1 mutations and copy number alterations (CNA) in a cohort of 5644 NSCLC patients. They found that XPO1 alterations were present in 2.8% of the cohort, with XPO1 CNAs being more common in lung squamous cell carcinoma (LUSC) compared to lung adenocarcinoma (LUAD). XPO1 mutations, on the other hand, had similar prevalence in both subtypes. Male patients were more likely to have XPO1 CNAs.<br /><br />The study also investigated the association between XPO1 alterations and patient survival. The researchers analyzed survival data from 3517 NSCLC patients and found that XPO1 mutations did not impact overall survival (OS). However, there was a significant negative association between XPO1 CNAs and OS, indicating that patients with XPO1 CNAs had worse clinical outcomes.<br /><br />Furthermore, the researchers examined the tumor infiltration of immune cells in NSCLC patients with XPO1 CNAs using the TIMER database. They found that in LUAD, XPO1 alterations were associated with lower levels of B cells, CD4 T cells, CD8 T cells, and dendritic cells. In LUSC, XPO1 alterations were associated with higher levels of B cells, CD8 T cells, CD4 T cells, and dendritic cells. These findings suggest that XPO1 alterations may affect the immune response in NSCLC patients.<br /><br />Overall, this study highlights the importance of XPO1 alterations as prognostic markers in NSCLC patients. The findings suggest that XPO1 CNAs are associated with reduced immune cell infiltration and worse clinical outcomes, while XPO1 mutations do not impact patient survival. Further research is needed to understand the underlying mechanisms and potential therapeutic implications of these alterations in NSCLC.

Asset Subtitle

Xuanzong Li

Meta Tag

Speaker Xuanzong Li

Topic Tumour Biology and Biomarkers - Immune Biology & Immunotherapy

Keywords

XPO1 gene alterations

immune cell infiltration

prognosis

NSCLC

XPO1 mutations

copy number alterations

LUAD

XPO1 CNAs

clinical outcomes

immune response